Avere Therapeutics announced a $500 million private placement to advance AVR-001, its once-weekly oral IL-23 receptor antagonist for inflammatory diseases. Leading healthcare investors including Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, and Wellington Management participated in the funding round. Combined with a previously announced $320 million concurrent private investment, the proceeds will fully fund Avere's operations through 2029. The financing will close alongside Avere's merger with NextCure, expected in the second half of 2026. Upon completion, the combined company will operate as Avere Therapeutics and trade on Nasdaq under ticker symbol "AVRX." Avere is initially developing AVR-001 for psoriasis, with potential expansion into ulcerative colitis, Crohn's disease, and psoriatic arthritis.

Tarsus Pharmaceuticals has secured $125 million through an oversubscribed private placement equity financing. The transaction includes participation from investors in Alkeus Pharmaceuticals, which Tarsus announced it would acquire earlier the same day. Notable investors include TCGX, Bain Capital Life Sciences, Wellington Management, ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital. The company is selling 2,098,519 shares of common stock at $56 per share and pre-funded warrants to purchase 133,625 additional shares. The financing is expected to close on 7 August 2026. Tarsus intends to use the proceeds to fund clinical development, commercial activities, and general corporate purposes. Barclays is serving as lead placement agent, with BofA Securities and William Blair as co-placement agents.